

Amendment to Specification

Please replace lines 7 through 10 of page 9 with the following amended paragraph:

(2R,2S)-N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 7);

(2R,2S)-N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-(N-methyl) phenylacetamide hydrochloride salt (Compound No. 8);

Please replace lines 21 through 27 on page 14 with the following amended paragraph to which spectroscopic data has been added for Compound No. 7 after line 22 and before "Example 3:"

(2R,2S)-N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 7)

¹HNMR spectral data showed (CDCl₃): δ 7.42-7.26 (m, 5H), 3.53-2.77 (m, 9H); 1.82-0.90 (m, 12H).

Example 3: (2R,2S)-N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-(N-methyl) phenylacetamide hydrochloride salt (Compound No. 8)

To a solution of (2R,2S)-N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-